Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in ...

Net sales of Cobenfy, whose success is imperative for Bristol Myers, totaled $27 million in the first quarter, handily ...

Bristol-Myers Squibb Company BMY reported first-quarter 2025 adjusted earnings per share (EPS) of $1.80, which comfortably beat the Zacks Consensus Estimate of $1.51. In the year-ago quarter, BMY ...

The Centers for Medicare & Medicaid Services will begin holding closed-door meetings this week with patients who use the 15 drugs it selected for the second round of Medicare price ...

Pfizer Inc. stock hits a 12-year low due to M&A missteps and high debt. Click here to find out why I rate PFE stock a Hold.

Drugmakers have been warned that the Trump Administration is considering linking U.S. medicine prices to lower amounts paid ...

Health officials in US President Donald Trump's administration are reportedly exploring an international reference pricing ...

Bristol-Myers Squibb (BMY) stock is down 11% year-to-date as the company navigates several looming patent cliffs. After a $13 ...